BRPI0415277A - célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo - Google Patents

célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo

Info

Publication number
BRPI0415277A
BRPI0415277A BRPI0415277-8A BRPI0415277A BRPI0415277A BR PI0415277 A BRPI0415277 A BR PI0415277A BR PI0415277 A BRPI0415277 A BR PI0415277A BR PI0415277 A BRPI0415277 A BR PI0415277A
Authority
BR
Brazil
Prior art keywords
isolated
gamma carboxylated
producing
protein
pharmaceutical composition
Prior art date
Application number
BRPI0415277-8A
Other languages
English (en)
Inventor
Christel Fenge
Ann Loevgren
Andrers Thelin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29559260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415277(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0415277A publication Critical patent/BRPI0415277A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"CéLULA, VETOR, MéTODO PAPA PRODUZIR PROTEìNA GAMACARBOXILADA, PROTEìNA GAMA-CARBOXILADA ISULADA, USO DA MESMA, MéTODO PARA PRODUZIR UMA COMPOSIçãO FARMACêUTICA, COMPOSIçãO FARMACêUTICA, MéTODO PARA PRODUZIR FATOR X DE HUMANO GAMA-CARBOXILADO, USO DE FATOR X ISOLADO, MéTODO PARA PRODUZIR PROTROMBINA DE HUMANO GAMA-CARBOXILADA, USO DE PROTROMBINA ISOLADA, E, MéTODO PARA PROMOVER COAGULAçãO AUMENTADA OU DIMINUìDA EM UM INDIVìDUO". A presente invenção refere-se aos métodos e às ferramentas para produzir quantidades grandes de proteina gama-carboxilada compreendendo: (i) cultivar uma célula adaptada para expressar uma proteína que requer gama-carboxilação e <sym>-glutamil-carboxilase em uma razão de pelo menos 10:1, sob condições adequadas para a expressão de ambas proteínas; e (ii) isolar a proteína gama-carboxilada.
BRPI0415277-8A 2003-10-14 2004-10-12 célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo BRPI0415277A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324044.7A GB0324044D0 (en) 2003-10-14 2003-10-14 Protein
PCT/SE2004/001453 WO2005038019A1 (en) 2003-10-14 2004-10-12 Method for producing gamma-carboxylated proteins

Publications (1)

Publication Number Publication Date
BRPI0415277A true BRPI0415277A (pt) 2006-12-19

Family

ID=29559260

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415277-8A BRPI0415277A (pt) 2003-10-14 2004-10-12 célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo

Country Status (28)

Country Link
US (2) US7842477B2 (pt)
EP (2) EP2292748B1 (pt)
JP (1) JP4658946B2 (pt)
KR (1) KR101201020B1 (pt)
CN (2) CN102443548B (pt)
AR (1) AR046180A1 (pt)
AT (1) ATE491789T1 (pt)
AU (2) AU2004281350B2 (pt)
BR (1) BRPI0415277A (pt)
CA (1) CA2541764C (pt)
CO (1) CO5690657A2 (pt)
DE (1) DE602004030603D1 (pt)
DK (1) DK1678297T3 (pt)
ES (2) ES2357603T3 (pt)
GB (1) GB0324044D0 (pt)
IL (2) IL174633A (pt)
IS (1) IS8447A (pt)
MX (1) MXPA06004060A (pt)
MY (1) MY141859A (pt)
NO (1) NO339740B1 (pt)
NZ (2) NZ546584A (pt)
PL (1) PL1678297T3 (pt)
PT (1) PT1678297E (pt)
RU (2) RU2372401C2 (pt)
TW (1) TWI355419B (pt)
UY (1) UY28558A1 (pt)
WO (1) WO2005038019A1 (pt)
ZA (1) ZA200603038B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2380985E (pt) * 2003-09-23 2014-03-26 Univ North Carolina Células que expressam a vitamina k epóxido reductase e sua utilização
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
CA2601574C (en) * 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
WO2006110083A1 (en) 2005-04-13 2006-10-19 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
AU2006298160A1 (en) * 2005-09-30 2007-04-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for preparing recombinant human thrombin with culture cell
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
PL1969127T5 (pl) * 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
EP1996186A4 (en) * 2006-03-06 2009-07-22 Humagene Inc PROCESS FOR THE PREPARATION OF RECOMBINANT HUMAN THROMBIN AND FIBRINOGEN
CA2683423C (en) * 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
MX343784B (es) 2010-10-06 2016-11-23 Medimmune Ltd Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos.
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
CA2847818A1 (en) * 2011-09-06 2013-03-14 Medimmune, Llc Methods for processing coagulation factors
RU2500816C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАК380, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1E6 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ РЕКОМБИНАНТНОГО ФАКТОРА IХ
JP5830486B2 (ja) 2013-03-29 2015-12-09 シスメックス株式会社 組換えバキュロウイルスおよびその利用
SG11201604218RA (en) * 2013-12-20 2016-07-28 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
CN109207462B (zh) * 2018-08-01 2021-05-11 深圳市新产业生物医学工程股份有限公司 异常凝血酶原及其制备方法和包含其的检测剂、试剂盒及应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (de) 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4599308A (en) * 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
DE3584341D1 (de) * 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US6224864B1 (en) * 1986-12-03 2001-05-01 Pharmacia & Upjohn Company Antibiotic 10381A, and process for the preparation of anitbiotics 10381B
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5118614A (en) * 1988-01-18 1992-06-02 Tessek Sdruzeni Praha Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
EP0540650A1 (en) 1990-07-23 1993-05-12 Zymogenetics, Inc. Gamma-carboxylase and methods of use
WO1998035689A1 (en) * 1997-02-14 1998-08-20 American Red Cross Expression of active human factor ix in mammary tissue of transgenic animals
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
JP2002500011A (ja) 1997-12-24 2002-01-08 イミュネックス・コーポレーション Ｖ２０１ｄｎａ及びポリペプチド
US6413737B1 (en) * 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
AU6366100A (en) 1999-07-23 2001-02-13 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
AU2001268373A1 (en) * 2000-06-13 2001-12-24 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
EP1325127B1 (en) 2000-10-02 2009-03-11 Novo Nordisk Health Care AG Method for the production of vitamin k-dependent proteins
WO2003004641A1 (en) 2001-07-06 2003-01-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing human thrombin by gene modification technique
KR101054735B1 (ko) 2001-07-06 2011-08-05 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 유전자 재조합 에카린 및 그를 제조하는 방법
WO2003006054A1 (en) 2001-07-10 2003-01-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
PT2380985E (pt) * 2003-09-23 2014-03-26 Univ North Carolina Células que expressam a vitamina k epóxido reductase e sua utilização
DK2189523T3 (da) 2003-10-14 2012-03-12 Baxter Int VKORC1 (vitamin K-epoxid-tilbageføringspolypeptid), et terapeutisk mål for coumarin og dets derivater
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP2180045B1 (en) 2003-10-24 2015-12-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Novel protein highly producing recombinant animal cell, method for preparing the same and method for mass-producing protein using the same
EP1831363A1 (en) 2004-12-21 2007-09-12 Novo Nordisk Health Care AG Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
WO2006110083A1 (en) * 2005-04-13 2006-10-19 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
ATE486128T1 (de) 2005-12-02 2010-11-15 Univ Wake Forest Health Sciences Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
PL1969127T5 (pl) * 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin

Also Published As

Publication number Publication date
RU2009123931A (ru) 2010-12-27
TW200523365A (en) 2005-07-16
ES2532470T3 (es) 2015-03-27
MY141859A (en) 2010-07-16
IL174633A (en) 2013-06-27
GB0324044D0 (en) 2003-11-19
EP2292748A1 (en) 2011-03-09
PT1678297E (pt) 2011-03-15
NO20061470L (no) 2006-05-12
CN102443548B (zh) 2014-03-12
PL1678297T3 (pl) 2011-11-30
AU2004281350A1 (en) 2005-04-28
JP4658946B2 (ja) 2011-03-23
CN102443548A (zh) 2012-05-09
IS8447A (is) 2006-05-10
ES2357603T3 (es) 2011-04-28
NO339740B1 (no) 2017-01-30
RU2372401C2 (ru) 2009-11-10
US7842477B2 (en) 2010-11-30
CA2541764C (en) 2015-03-31
CO5690657A2 (es) 2006-10-31
US20110092429A1 (en) 2011-04-21
JP2007508820A (ja) 2007-04-12
AU2004281350B2 (en) 2008-05-15
DK1678297T3 (da) 2011-03-14
AR046180A1 (es) 2005-11-30
NZ546584A (en) 2009-08-28
KR101201020B1 (ko) 2012-11-14
CN1867669B (zh) 2011-10-19
TWI355419B (en) 2012-01-01
IL174633A0 (en) 2006-08-20
DE602004030603D1 (de) 2011-01-27
IL226313A0 (en) 2013-06-27
AU2008205445A1 (en) 2008-09-04
CN1867669A (zh) 2006-11-22
MXPA06004060A (es) 2006-06-28
CA2541764A1 (en) 2005-04-28
NZ578306A (en) 2011-02-25
US20050164367A1 (en) 2005-07-28
EP1678297B1 (en) 2010-12-15
ZA200603038B (en) 2007-09-26
US8697440B2 (en) 2014-04-15
ATE491789T1 (de) 2011-01-15
HK1155475A1 (en) 2012-05-18
KR20060123152A (ko) 2006-12-01
EP1678297A1 (en) 2006-07-12
WO2005038019A1 (en) 2005-04-28
EP2292748B1 (en) 2014-12-17
RU2006110147A (ru) 2007-11-20
UY28558A1 (es) 2005-05-31

Similar Documents

Publication Publication Date Title
BR0108713A (pt) Expressão hìbrida de proteìnas de neisseria
EP1687283A4 (en) FOR THE DETERMINATION OF FK506 PROCEDURE AND COMPOSITION
ATE541934T1 (de) Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
NO20043245L (no) Bindingsproteiner som biosensorer
WO2021194826A3 (en) Recombinant sars-cov-2 spike protein and uses thereof
CY1114701T1 (el) Συνθεσεις και μεθοδοι για αυξηση ασβεστοποιησης οστων
BR0105603A (pt) Sistema e método de informação para piloto, atuado por olhar fixo sem mostrador visual
BRPI0513029A (pt) método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
BRPI0315652B8 (pt) molécula de ácido nucleico isolada, vetor, polipeptídeo de fusão, e, multímero
ATE485331T1 (de) Thiolselektive wasserlösliche polymerderivate
BR0213207A (pt) remodelagem e glicoconjugação de peptìdeos
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
BR112021018608A2 (pt) Anticorpos para claudina-6 e conjugados de fármaco
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
BRPI0413644A (pt) métodos para separar as duas formas de um polipeptìdeo tendo uma única racemização de aminoácido, e para separar dois polipeptìdeos, produto de polipeptìdeo, e, composição farmacêutica
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BRPI0810130A8 (pt) Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida
GEAP202516650A (en) Stabilized pre-fusion hmpv fusion proteins
EP4534972A3 (en) Synthetic controls for immunohistochemistry
DK1546373T3 (da) Fremgangsmåder til måling af hastigheder af revers cholesteroltransport in vivo som et indeks for antiatherogenese
BRPI0519429A2 (pt) composiÇço adequada para melhorar funÇço renal em um animal, mÉtodo para melhorar a funÇço renal em um animal, kit adequado para administrar composiÇÕes para melhorar a funÇço renal a um animal, meio para comunicar informaÇço, e, uso de uma composiÇço
UY28558A1 (es) Proteína
BR0315178A (pt) Eritropoietina: remodelagem e glicoconjugação de eritropoietina
BR0210905A (pt) Anticorpos especìficos para cd44v6

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 9/64

Ipc: C12N 9/64 (2006.01), C12N 9/74 (2006.01), C12P 21/

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.